Business Context and Reporting Period
Company: Jackson Acquisition Company II (JACS)
Reporting Period: Quarter ended September 30, 2024 (Inception: September 11, 2024)
Business Type: Cayman Islands exempted company (Blank Check/SPAC) focused on healthcare services and technology.
Status: Pre-operational. The company was formed to effect a business combination. As of the balance sheet date, no operations had commenced, and no revenues were generated.
Key Financial Metrics
| Metric | Value |
|---|---|
| Total Assets | $193,800 |
| Total Liabilities | $218,368 |
| Shareholders' Deficit | ($24,568) |
| Net Loss (Inception to 9/30/24) | ($49,568) |
| Cash and Cash Equivalents | $0 |
| Working Capital Deficit | ($215,119) |
| Promissory Note (Related Party) | $120,368 |
Material Changes and Subsequent Events
The financial statements reflect the pre-IPO formation period. Significant capital events occurred subsequent to the reporting period (December 11, 2024):
- Initial Public Offering (IPO): Consummated on December 11, 2024. Sold 23,000,000 Units (including full over-allotment) at $10.00 per unit, generating gross proceeds of $230,000,000.
- Private Placement: Simultaneously sold 840,000 Private Placement Units to the Sponsor and underwriters for $8,400,000.
- Trust Account: $232,300,000 was deposited into the Trust Account following the IPO.
- Transaction Costs: Total transaction costs amounted to $5,157,741 ($4,600,000 underwriting fee + $557,741 other costs).
- Founder Shares: 750,000 Class B shares previously subject to forfeiture were retained following the full exercise of the over-allotment option.
Outlook, Risks, and Contingencies
- Going Concern: As of September 30, 2024, the company had no cash and a working capital deficit. However, management concluded that the successful closing of the IPO on December 11, 2024, provides sufficient funds for working capital needs for at least one year.
- Business Combination Deadline: The company has 24 months from the IPO closing (December 11, 2024) to complete a business combination. Failure to do so will result in liquidation and redemption of public shares.
- Geopolitical Risks: The filing highlights risks associated with the Russia-Ukraine conflict and Israel-Hamas conflict, which could impact global markets and the ability to find a target.
- Related Party Obligations: The Sponsor has agreed to indemnify the Trust Account against certain third-party claims to ensure funds remain at least $10.10 per share. The Sponsor also pays $10,000/month for administrative services.
Investor Verification Checklist
- IPO Closing Confirmation: Verify the final closing date and total proceeds of the December 11, 2024 IPO and Private Placement.
- Trust Account Balance: Confirm the exact amount held in the Trust Account ($232,300,000) and the interest-bearing status of the funds.
- Share Structure: Verify the final count of Class A (Public) and Class B (Founder) shares outstanding post-IPO.
- Related Party Debt: Confirm the status of the $120,368 promissory note to the Sponsor and whether it was repaid or converted upon IPO.
- Target Search: Monitor for announcements regarding the identification of a target business within the healthcare sector.